Merck, 69454-3, HMS174(DE3)pLysS Competent Cells - Novagen

General description
Genotype: F⁻recA1 hsdR(rK₁₂⁻ mK₁₂⁺) (DE3) pLysS (CamR, Rif R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
HMS174 strains provide the recA mutation in aK-12 background. Like BLR, these strains maystabilize certain target genes whose productsmay cause the loss of the DE3 prophage.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
HMS174 strains provide high transformation efficiencies and the recA mutation in a K-12 background. T7 lysozyme expression suppresses basal T7 expression.
Other Notes
0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlHMS174(DE3)pLysS Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)